Jump Financial LLC Takes $2.84 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Jump Financial LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 62,809 shares of the biopharmaceutical company's stock, valued at approximately $2,835,000. Jump Financial LLC owned 0.08% of PTC Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of PTC Therapeutics by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,798,666 shares of the biopharmaceutical company's stock worth $66,743,000 after acquiring an additional 10,886 shares during the period. Diversified Trust Co increased its holdings in shares of PTC Therapeutics by 10.4% in the 4th quarter. Diversified Trust Co now owns 16,818 shares of the biopharmaceutical company's stock worth $759,000 after acquiring an additional 1,578 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of PTC Therapeutics by 8.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 5,965 shares of the biopharmaceutical company's stock worth $269,000 after acquiring an additional 455 shares during the period. KBC Group NV increased its holdings in shares of PTC Therapeutics by 36.4% in the 4th quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company's stock worth $137,000 after acquiring an additional 813 shares during the period. Finally, R Squared Ltd acquired a new stake in shares of PTC Therapeutics in the 4th quarter worth about $79,000.

PTC Therapeutics Stock Up 2.2 %

PTC Therapeutics stock traded up $1.07 during mid-day trading on Wednesday, hitting $49.26. The company's stock had a trading volume of 105,896 shares, compared to its average volume of 809,018. The stock has a market capitalization of $3.89 billion, a P/E ratio of -8.29 and a beta of 0.58. PTC Therapeutics, Inc. has a twelve month low of $24.00 and a twelve month high of $58.38. The stock's fifty day moving average price is $50.15 and its two-hundred day moving average price is $46.33.

Insiders Place Their Bets

In other PTC Therapeutics news, EVP Lee Scott Golden sold 897 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total transaction of $42,114.15. Following the transaction, the executive vice president now directly owns 75,997 shares in the company, valued at approximately $3,568,059.15. The trade was a 1.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Pierre Gravier sold 1,168 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total transaction of $58,516.80. Following the transaction, the chief financial officer now owns 75,603 shares in the company, valued at approximately $3,787,710.30. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 29,501 shares of company stock worth $1,546,088. 5.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. StockNews.com cut shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Morgan Stanley reiterated an "overweight" rating and issued a $70.00 target price (up previously from $67.00) on shares of PTC Therapeutics in a research report on Friday, March 7th. Citigroup increased their target price on shares of PTC Therapeutics from $32.00 to $45.00 and gave the company a "sell" rating in a research report on Wednesday, February 12th. Scotiabank began coverage on shares of PTC Therapeutics in a research report on Friday, March 7th. They issued a "sector perform" rating and a $55.00 target price for the company. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $65.00 target price on shares of PTC Therapeutics in a research report on Tuesday. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $63.92.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.